Fulgent Genetics (NASDAQ:FLGT) Releases FY25 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) issued an update on its FY25 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of $(0.65) for the period, compared to the consensus estimate of ($0.15). The company issued revenue guidance of $310.0 million, compared to the consensus revenue estimate of $324.65 million. Fulgent Genetics also updated its FY 2025 guidance to -0.650--0.650 EPS.

Fulgent Genetics Trading Down 1.1 %

Shares of NASDAQ FLGT traded down $0.17 during midday trading on Monday, hitting $15.28. 568,179 shares of the company's stock were exchanged, compared to its average volume of 195,173. Fulgent Genetics has a 12-month low of $14.92 and a 12-month high of $25.11. The company has a market cap of $467.37 million, a price-to-earnings ratio of -2.77 and a beta of 1.39. The business's fifty day moving average price is $17.25 and its two-hundred day moving average price is $19.38.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on FLGT. StockNews.com lowered Fulgent Genetics from a "hold" rating to a "sell" rating in a research note on Wednesday, November 27th. Piper Sandler cut their target price on Fulgent Genetics from $26.00 to $22.00 and set a "neutral" rating for the company in a research note on Monday, November 11th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.